Androgenetic Alopecia Treatment Global Market Report 2024

The androgenetic alopecia treatment market size has grown strongly in recent years. It will grow from $2.13 billion in 2023 to $2.29 billion in 2024 at a compound annual growth rate (CAGR) of 7.5%. The growth during the historic period can be attributed to an emphasis on improving patient outcomes and quality of life, an increase in the geriatric population, and rising healthcare expenditure.

The androgenetic alopecia treatment market size is expected to see strong growth in the next few years. It will grow to $3.07 billion in 2028 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to the rising incidence of hair loss, the prevalence of chronic diseases such as cancer, polycystic ovary syndrome (PCOS), and rheumatoid arthritis, as well as the demand for effective solutions to address hair loss concerns. Major trends expected during the forecast period include partnerships, product approvals, investments, and advancements in research and development.

The increasing incidence of hair loss cases is projected to drive the growth of the androgenetic alopecia treatment market in the future. Alopecia, or hair loss, refers to the partial or complete loss of hair from the scalp or other parts of the body. Causes of hair loss include nutritional deficiencies, hormonal fluctuations, genetic predispositions, and heightened stress levels. Androgenetic alopecia treatments employ various methods, including hormonal regulation, follicle stimulation, and surgical interventions, to manage hair loss and stimulate regrowth. For example, as reported in March 2022 by the Hair Society, an organization based in the US, approximately 21 million women and 35 million men worldwide are affected by hair loss. Additionally, in 2024, according to the National Health Service, a government agency in the UK, around 8 million women and 6.5 million men in the UK experience hair loss. Moreover, over 650,000 hair transplants are performed annually. Hence, the increasing prevalence of hair loss cases propels the androgenetic alopecia treatment market.

Key players in the androgenetic alopecia treatment market are actively developing innovative drug options to address hair loss. These options target mechanisms such as promoting hair follicle regeneration, inhibiting hormones responsible for hair loss, and utilizing novel delivery systems such as topical treatments and oral medications. For instance, in June 2023, Pfizer Inc., a healthcare company based in the US, announced the FDA approval of LITFULO (ritlecitinib), a once-daily oral treatment for individuals aged 12 and above with severe alopecia areata. LITFULO is a kinase inhibitor that targets Janus kinase 3 (JAK3) and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) family of kinases. The FDA approval was based on the ALLEGRO Phase 2b/3 trial, where 23% of patients treated with LITFULO 50mg achieved 80% or more scalp hair coverage after six months, compared to 1.6% with placebo. This solution offers a new option for individuals experiencing significant hair loss, addressing a previously unmet need in alopecia areata treatment.

In April 2023, Marksans Pharma, an India-based pharmaceutical company, acquired a manufacturing facility from Tevapharm India for an undisclosed sum. This strategic acquisition enabled Marksans Pharma to double its existing manufacturing capacity in India and broaden its product range to include tablets, capsules, ointments, liquids, and creams. Teva Pharmaceuticals, based in Israel, provides treatments for androgenetic alopecia.

Major companies operating in the androgenetic alopecia treatment market are Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Eli Lilly and Company, Daiichi-Sankyo Co. Ltd., Sun Pharmaceutical Industries Ltd., Allergan Plc, Aurobindo Pharma Limited, Dr Reddy's Laboratories Ltd., Cipla Limited, Fagron Inc., Vitabiotics Ltd., Cosmo Pharmaceuticals NV, Aclaris Therapeutics Inc., Curallux LLC, PureTech Health, Technoderma Medicines Inc., Theradome Inc., Lexington International, HCell Inc., Follica Inc., Ranbaxy Laboratories Ltd., Apira Science Inc., Freedom Laser Therapy Inc., Histogen Inc.

North America was the largest region in the androgenetic alopecia treatment market in 2023. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the androgenetic alopecia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the androgenetic alopecia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Androgenetic alopecia, also referred to as male-pattern baldness or female-pattern hair loss, is a prevalent form of hair loss affecting both men and women. It is characterized by a gradual thinning of the hair, commonly starting with a receding hairline in men and diffuse thinning over the crown in women. Genetic factors and the presence of androgens, particularly dihydrotestosterone (DHT), play significant roles in this condition.

The primary treatments for androgenetic alopecia include pharmaceuticals and devices. Pharmaceuticals encompass substances used in healthcare, typically medicinal drugs or chemical compounds. These medications are available in both prescription and over-the-counter forms and are utilized by both males and females. They find applications in various end-user industries, including homecare settings, dermatology, clinics, and others.

The androgenetic alopecia treatment market research report is one of a series of new reports that provides androgenetic alopecia treatment market statistics, including androgenetic alopecia treatment industry global market size, regional shares, competitors with an androgenetic alopecia treatment market share, detailed androgenetic alopecia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the androgenetic alopecia treatment industry. This androgenetic alopecia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The androgenetic alopecia treatment market consists of sales of microneedling devices, hair growth vitamins, and supplements. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.